138 related articles for article (PubMed ID: 36811384)
1. T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.
Teng X; Rong Z; Li S; Yang W; Lu Z
Immunol Cell Biol; 2023 May; 101(5):458-464. PubMed ID: 36811384
[TBL] [Abstract][Full Text] [Related]
2. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
3. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
4. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
[TBL] [Abstract][Full Text] [Related]
5. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
7. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
9. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
11. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
[TBL] [Abstract][Full Text] [Related]
12. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
14. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
15. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
16. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
17. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
18. Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.
Jiang G; Ng YY; Tay JCK; Du Z; Xiao L; Wang S; Zhu J
Cancer Immunol Immunother; 2023 Jan; 72(1):223-234. PubMed ID: 35809118
[TBL] [Abstract][Full Text] [Related]
19. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer.
Zhang Y; Li X; Zhang J; Mao L
Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
[TBL] [Abstract][Full Text] [Related]
20. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
